About NEC OncoImmunity AS

Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies.

NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. The AI technology can be used to identify optimal antigen/epitope targets for infectious disease vaccines, truly personalized cancer vaccines & T cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy.

NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway.

Leadership
Advisors
Team

NEC OncoImmunity AS has assembled a growing and experienced multidisciplinary team of bioinformaticians, software-engineers and data scientists with machine-learning expertise.

Saverio Niccolini, Ph.D.

CEO
Stig Jarle Pettersen

CFO
Akira Kitamura

Executive Chairperson of the Board

Dr. Saverio Niccolini holds a PhD in telematics from University of Pisa. He has over two decades of experience in the technology research and development sector. Since joining NEC in 2004, he has played a pivotal role in steering the company's strategic direction in the fields of artificial intelligence, system platforms, and life sciences. At NEC OncoImmunity AS, he oversees the operational strategies that drive the development of innovative cancer and infectious disease therapies where cutting-edge AI technology meets drug development, enhancing NEC's footprint in the healthcare industry. Concurrently, as General Manager at NEC Laboratories, Saverio leads initiatives that bridge the gap between fundamental AI research and practical applications across various industry verticals, fostering a culture of innovation and technical excellence with a passion for transformative technology.

Mr Pettersen is a graduate of the Norwegian School of Economics & Business Administration. He is an executive member of the board in Affitech AS. Mr. Pettersen is also on the board of Actigen Ltd. Previously Mr. Pettersen held the position of Chief Financial Officer of Xellia Pharmaceuticals AS and Chief Financial Officer for Cermaq ASA.

.

A development environment deeply immersed in the combined scientific fields of bioinformatics, biotechnology, onco-immunology and data science

Richard Stratford Ph.D.

Co-founder & Advisor
Trevor Clancy Ph.D.

Co-founder & Advisor

Dr. Stratford holds a PhD degree in immunology from Imperial College London. He has more than 12 years of experience in the vaccine industry and more than 16 years of commercial experience in biotechnology. In addtion Dr. Stratford has extensive experience in business development & patent management.

- Shuffle -